International Journal of Cardiology
Volume 136, Issue 2 , Pages 115-119 , 14 August 2009

The importance of considering alternative or combination strategies for lowering LDL-C

  • Kwang Kon Koh

      Affiliations

    • Division of Cardiology, Gachon University, Gil Medical Center, Incheon, South Korea
    • Corresponding Author InformationCorresponding author. Vascular Medicine and Atherosclerosis Unit, Division of Cardiology, Gachon University, Gil Medical Center, 1198 Kuwol-dong, Namdong-gu, Incheon, South Korea 405-760. Tel.: +82 32 460 3683; fax: +82 32 460 3117.
    • ,
  • Michael J. Quon

      Affiliations

    • Diabetes Unit, NCCAM, NIH+, Bethesda, Maryland, USA

Received 22 February 2009 ,Accepted 4 March 2009.

References 

  1. Steinberg D. The statins in preventive cardiology. N Engl J Med. 2008;359:1426–1427
  2. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation. 2008;118:672–677
  3. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409–418
  4. Rossebø AB, Pedersen TR, Boman K, et al. SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–1356
  5. La Rosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  6. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation. 1992;86:1046–1060
  7. D'Agostino RB, Belanger AJ, Kannel WB, Higgins M. Role of smoking in the U-shaped relation of cholesterol to mortality in men. The Framingham study. Am J Epidemiol. 1995;141:822–827
  8. Wannamethee G, Shaper AG, Whincup PH, Walker M. Low serum total cholesterol concentrations and mortality in middle aged British men. BMJ. 1995;311:409–413
  9. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80
  10. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol. 2008;52:1141–1147
  11. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  12. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005;46:106–112
  13. Wanner C, Krane V, März W, et al. German Diabetes and Dialysis Study Investigators. atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  14. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  15. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687–3692
  16. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 2005;45:1088–1093
  17. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of patients with combined hyperlipidemia. J Am Coll Cardiol. 2005;45:1649–1653
  18. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005;46:1978–1985
  19. Han SH, Quon MJ, Kim J, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol. 2007;49:531–538
  20. Rodriguez-Porcel M, Lerman LO, Herrmann J, Sawamura T, Napoli C, Lerman A. Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol. 2003;23:885–891
  21. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–1904
  22. Koh KK, Quon MJ. Combination therapy for treatment or prevention of atherosclerosis. Hypertension. 2008;52:e18
  23. Koh KK, Quon MJ. Targeting converging therapeutic pathways to overcome hypertension. Int J Cardiol. 2009;132:297–299
  24. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(09)00291-5

doi: 10.1016/j.ijcard.2009.03.035

International Journal of Cardiology
Volume 136, Issue 2 , Pages 115-119 , 14 August 2009

Article Tools

* Image Usage & Resolution